

# WEALTH WEEKLY

## Weekly Alerts You Can Use!

### Weekly View: Nifty, Bank Nifty:

| Indices    | CMP   | Support | Resistance | 50 DMA | 200 DMA | Range       | Preferred Trade  |
|------------|-------|---------|------------|--------|---------|-------------|--|
| NIFTY      | 24719 | 24399   | 25000      | 24278  | 24083   | 24422-24899 | Buy between 24422-24444 zone. Targets at 27880/25001. Stop at 24211. |
| BANK NIFTY | 55527 | 53900   | 56771      | 54518  | 51778   | 55522-57111 | Sell at CMP. Targets at 53900/52401/51375. Stop 56781                |

### Medium Term Pick:

| Stocks | CMP  | Support | Resistance | 50 DMA | 200 DMA | Bias     | Preferred Trade  |
|--------|------|---------|------------|--------|---------|----------|--|
| ALIVUS | 1014 | 783     | 1335       | 1059   | 1077    | Positive | <b>Alivus Life Sciences Limited (Formerly Glenmark Life Sciences Limited)</b> , is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. The company is increasingly providing CDMO services to a range of multinational and specialty pharmaceutical companies. It has a diversified portfolio of 161 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW). The company's four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of 1424 KL, which are regularly inspected by global regulators such as USFDA, PMDA (Japan) and EDQM (Europe). The Q4 performance reflects this renewed energy, with growth across both GPL and Non-GPL segments. Geographically, regions like India, Europe, ROW and Japan contributed to the growth. The firm reported Net profit which rose 44.85% to Rs 141.87 crore in the quarter ended March 2025 as against Rs 97.94 crore during the previous quarter ended March 2024. Sales rose 21.05% to Rs 649.55 crore in the quarter ended March 2025 as against Rs 536.60 crore during the previous quarter ended March 2024. <b>Establish long positions at CMP, targeting 1121/1335 and then aggressive targets at psychological 1500 mark. Stop below 783. Holding Period: 12-15 Months.</b> |

#### BUY ALIVUS CMP 1014, Target 1335

|                                     |                       |
|-------------------------------------|-----------------------|
| CMP                                 | 1014                  |
| Target Price                        | 1335                  |
| 52 Week H/L                         | 1335/820.05           |
| P/E                                 | 25.53                 |
| EPS (TTM)                           | 39.60                 |
| Promoter Holding/DIIs/FIIs          | 74.99/5.2/6.6         |
| Promoter Holding/DIIs/FIIs/Promoter | 75%/5.19%/6.57%/13.25 |
| Book Value                          | 230                   |
| Market Cap (INR)                    | 12437 Cr              |
| Holding Period                      | 12-15 Months          |

#### Daily Chart of ALIVUS :



**Theme:** Incorporated in the year 2011, Alivus Life Sciences Limited, formerly Glenmark Life Sciences, is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes.

The company is increasingly providing CDMO services to a range of multinational and specialty pharmaceutical companies. It has a diversified portfolio of 159 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan and the Rest of the World (RoW). The company's 4 manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of 1,424 KL, which are regularly inspected by global regulators such as USFDA, PMDA (Japan) and EDQM (Europe).

Alivus partners with the world's top 20 generic companies & serves customers in multiple geographies including North America, Europe, Japan, Latin America, India and ROW.

#### Alivus delivered strong performance:

- Revenue: Rs 649.63 crore, up 21.1% YoY.
- EBITDA: Rs 2,085 million, up 44.2% YoY.
- EBITDA Margin: 32.1%, up 520 bps YoY.
- Net Profit: Rs 141.9 million.
- PAT Margin: 21.8%.
- QoQ Growth: Revenue saw a 1.2% QoQ increase, while EBITDA increased by 3.8%.
- The company has a strong focus on organic expansion and building its own plants.
- Management expects mid-teen volume growth for Fy26.
- While pricing pressures and regulatory concerns exist, the company is optimistic about its future growth.
- The company is net debt-free and has a strong cash flow.

**Technical Outlook:** Alivus Life Sciences has been amongst the top outperformers amongst the Pharma space with the stock price giving a Return of Equity (ROE) in last five financial years given by was 17.23%, 20.18%, 21.83%, 20.38% and 46.7% respectively. Alivus stock price gave a 3 year return of 120.18% as compared to Nifty 50 which gave a return of 50.77%. Alivus already gaining 3.13% YTD as against Nifty Pharma's loss of 6.10%. The 200 days Exponential Moving Average (EMA) of the stock on the daily chart is currently at 1031 zone. Any massive successive upside move is likely to provide decent buying opportunity.

**Preferred Strategy:** Establish long positions at CMP, targeting 1121/1335 and then aggressive targets at psychological 1500 mark. Stop below 783. Holding Period: 12-15 Months.

## Mehta Equities

903 Lodha Supremus, Dr. E Moses Road, Worli Naka, Mumbai - 400 018 Board: +91-22-61507100/101 Fax: +91-22-61507102